Efficacy of alternate day versus daily dosing of rosuvastatin

Canadian Journal of Cardiology

Volumn 25, Issue 2, 2009, Pages

  Dulay, Daisy ^a   LaHaye, Stephen A ^b,d   Lahey, Karen A ^b   Day, Andrew G ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c KINGSTON GENERAL HOSPITAL   (Canada)

^d HOTEL DIEU HOSPITAL   (Canada)

Author keywords

Dyslipidemia; LDL cholesterol; Rosuvastatin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MEDICAL DECISION MAKING; MYALGIA; PATIENT COMPLIANCE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; BLOOD; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG ADMINISTRATION; DRUG EFFECT; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PYRIMIDINES; SULFONAMIDES; TRIGLYCERIDES; YOUNG ADULT;

EID: 63049102033     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70480-5     Document Type: Article

References (25)

1. I. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002;360:7-22.
4. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
6. McPherson R, Frohlich J, Fodor G, Genest J. Canadian Cardiovascular Society position statement - Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-27.
7. Jones PH, Davidson MH, Stein EA, et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;93:152-60.
8. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87(Suppl B):28B-32B.
9. Miettinen TA. Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins. J Lipid Res 1982;23:466-73.
10. Neese RA, Faix D, Kletke C, et al. Measurement of endogenous synthesis of plasma cholesterol in rats and humans using MIDA. Am J Physiol 1993;264:E136-47.
11. Copher HR, Stewart RD. Daily dosing versus alternate-day dosing of simvastatin in patients with hypercholesterolemia. Pharmacotherapy 2002;22:1110-6.
12. Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J 2002;144:674-7.
13. Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M. Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther 2003;8:123-6.
14. Fleiss JL. The Design and Analysis of Clinical Experiments. New York: Wiley, 1986.
15. Hills M, Armitage P. The two-period crossover clinical trial. Br J Clin Pharmacol 1979;8:7-20.
16. Brown BW. The crossover experiment for clinical trials. Biometrics 1980;36:69-79.
17. SAS Institute Inc. SAS/STAT User's Guide, Version 8. Cary: SAS Institute Inc, 1999.
18. Olsson AG, McTaggart F, Raza A. Rosuvastatin: A highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303-28.
19. Cholesterol Treatment Trialists' (CCT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
20. Federman AD, Adams AS, Ross-Degnan D, Soumerai SB, Ayanian JZ. Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease. JAMA 2001;286:1732-9.
21. Soumerai SV, Ross-Degnan D, Avorn J, McLaughlin TJ, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 1991;325:1072-7.
22. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285:421-9.
23. Rector TS. Exhaustion of drug benefits and disenrollment of medicare beneficiaries from managed care organizations. JAMA 2000;283:2163-7.
24. Régis de l'assurance maladie du Québec. List of Medications. (Version current at January 7, 2009).
25. Alexander GC, Casalino LP, Meltzer DO. Physician strategies to reduce patients' out-of-pocket prescription costs. Arch Intern Med 2005;165:33-6.